Flerie AB (publ) (FLERIE) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to Clary's Q4 2024 report presentation. For those of you who potentially can see these rather annoying captions being run at the bottom, please just ignore them as we're actually running this in English. We are here with several different people in the audience, and that's why we're running this in English. So apologies for the combination Swedish-English captions. We're, of course, talking about FLIRI, our investment company, located here in Stockholm and active all over the world. We've just come back from the JP Morgan Healthcare Conference, excited for 2025, but now reporting our last quarter of 2024. The usual disclaimer, I hope you've all read this in detail. And let me just remind for the new shareholders and new people in the audience of who we are. We are a biotech and pharma investment company. We invest long term and that therefore we're also often called an evergreen investor. We're investing off our own balance sheet into 29 portfolio companies. And we have mostly private companies, 73%, in fact, out of our net asset value of almost 4.2 billion SEG. We were founded in 2011 and we got listed on the NASDAQ Stockholm main market in June 2024. So just half a year listed. We have a very diversified portfolio and that's the reason we got listed and made it possible for other shareholders to invest in us. It's because we indeed provide this risk diversification across different stages. in the pharmaceutical and biotech development area. As you can see here, most of our company, 16 in fact, are in later clinical stages, or in fact, even in commercial stage. We're run by a specialised team. All of us have worked in biotech and pharma for a very long time, several decades, most of us. We're experts in life science and we're supp...